PMID- 15777971
OWN - NLM
STAT- MEDLINE
DCOM- 20050712
LR  - 20151119
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 48
IP  - 1
DP  - 2005 Apr
TI  - HER2/neu expression and amplification in non-small cell lung cancer prior to and 
      after neoadjuvant therapy.
PG  - 59-67
AB  - BACKGROUND: Expression and amplification of the HER2/neu protooncogene was 
      analyzed in locally advanced NSCLC in a multimodality therapy approach in order 
      to obtain information on the predictive value of HER2/neu for success or failure 
      of neoadjuvant therapy. METHODS: In the scope of a prospective randomized phase 
      III-trial, tumor tissue of pre-therapeutically obtained mediastinal lymph node 
      biopsies (n=105) and corresponding post-surgical resection specimens (n=44) was 
      analyzed by means of immunohistochemistry (DAKO-Hercep-Test) and fluorescence in 
      situ hybridization (FISH). In 58 of 105 patients with metastatic mediastinal 
      lymph node disease the extent of therapy-induced tumor regression could be 
      established. RESULTS: Concerning HER2/neu expression, 16 lymph node biopsies 
      (15.2%) showed 1+, 2+, or 3+ results. Five of these cases revealed amplification 
      in FISH analysis (4.8%). In 44 corresponding resection specimens, Hercep-Test 
      showed 1+, 2+, or 3+ results in 13 tumors (29.5%). Two of these patients revealed 
      HER2/neu amplification in FISH analysis (4.5%). In patients with HER2/neu 
      expressing tumors a trend towards a less extensive therapy-induced tumor 
      regression could be demonstrated. When comparing pre-therapy and post-surgical 
      results, there was a weak trend towards a selection of HER2/neu expressing tumor 
      tissue in the course of neoadjuvant therapy. CONCLUSIONS: Only a limited 
      subcollective of locally advanced NSCLC meets the biological requirements for 
      anti-HER2/neu therapy. HER2/neu positive tumors appeared to be relatively 
      resistant to chemotherapy and radiation treatment, none of these cases having a 
      pathological complete or at least subtotal response in the corresponding 
      resection specimens. This observation requires confirmation in large randomized 
      controlled studies.
FAU - Junker, Klaus
AU  - Junker K
AD  - Institute of Pathology, Bergmannsheil-University-Hospital, 
      Burkle-de-la-Camp-Platz 1, D-44789 Bochum, Germany. 
      klaus.junker@ruhr-uni-bochum.de
FAU - Stachetzki, Ulf
AU  - Stachetzki U
FAU - Rademacher, Daniela
AU  - Rademacher D
FAU - Linder, Albert
AU  - Linder A
FAU - Macha, Hans-Nicol
AU  - Macha HN
FAU - Heinecke, Achim
AU  - Heinecke A
FAU - Muller, Klaus-Michael
AU  - Muller KM
FAU - Thomas, Michael
AU  - Thomas M
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20041213
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Lung Cancer. 2005 Aug;49(2):279-80. PMID: 16022924
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics/radiotherapy/surgery
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - *Gene Amplification
MH  - *Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*drug therapy/*genetics/radiotherapy/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Treatment Outcome
EDAT- 2005/03/22 09:00
MHDA- 2005/07/13 09:00
CRDT- 2005/03/22 09:00
PHST- 2004/05/06 00:00 [received]
PHST- 2004/10/06 00:00 [revised]
PHST- 2004/10/12 00:00 [accepted]
PHST- 2005/03/22 09:00 [pubmed]
PHST- 2005/07/13 09:00 [medline]
PHST- 2005/03/22 09:00 [entrez]
AID - S0169-5002(04)00535-5 [pii]
AID - 10.1016/j.lungcan.2004.10.010 [doi]
PST - ppublish
SO  - Lung Cancer. 2005 Apr;48(1):59-67. doi: 10.1016/j.lungcan.2004.10.010. Epub 2004 
      Dec 13.